Effects of trans-4-(aminomethyl) cyclohexanecarboxylic acid/potassium azeloyl diglycinate/niacinamide topical emulsion in Thai adults with melasma: a single-center, randomized, double-blind, controlled study

Viyoch, Jarupa; Tengamnuay, Isaree; Phetdee, Khemjira; Tuntijarukorn, Punpimol; Waranuch, Neti

doi:10.1016/s0011-393x(10)80001-3

Cited by 7 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four RCTs were found that assessed niacinamide. [ 26 120 121 122 ] However, two studies included patients with different causes of facial hyperpigmentation in addition to melasma[ 121 122 ] and another one evaluated a combination cream with niacinamide as one ingredient. [ 1 ] Thus, only one double-blind RCT evaluated efficacy of niacinamide monotherapy in melasma, and it compared the efficacy with 4% HQ [ Table 16 ].…”

Section: Chemical Peelsmentioning

confidence: 99%

Evidence-based review, grade of recommendation, and suggested treatment recommendations for melasma

Sarma

Chakraborty

Poojary

et al. 2017

Indian Dermatol Online J

View full text Add to dashboard Cite

Treatment of melasma is known to be less satisfactory, often incomplete, and relapse is frequent. Although many treatment options are available, they are either known to be unsafe on long-term use or their long-term safety profile is unknown. Patients often use various drugs, even topical steroid-based preparation without any medical supervision for long period of time, making the skin unsuitable for many of the drugs available. Thus, there has been gross disparity among the treating physician about what drugs and what regimen are best suitable for various categories of melasma patients and in different situations. With this background, numerous newer drugs, mostly combinations of some proprietary molecules or even unknown plant extracts, have flooded the market for the management of melasma. Information on efficacy or safety of these products are almost unknown. Studies on Asian people, especially Indian population, are far less commonly available. Therapeutic guideline for use on Indian patients with melasma is almost missing. Extrapolation of data from Caucasian people for use on Asian people may not be scientifically justifiable because Caucasian and Asian people are known to have inherent difference in their response as well as tolerance to the drugs used for melasma. With this background, we have extensively evaluated, following a strict, scientifically designed protocol, all the available studies on melasma management till May 2016 and prepared this document on level of evidence, grade of recommendation and suggested therapeutic guideline for melasma as per the method proposed by Oxford Centre of Evidence-Based Medicine. Various ethical, social, logical, regional, and economic issues in the context of Indian and similar populations were given due importance while preparing the suggested therapeutic recommendation.

show abstract

Section: Chemical Peelsmentioning

confidence: 99%

Evidence-based review, grade of recommendation, and suggested treatment recommendations for melasma

Sarma

Chakraborty

Poojary

et al. 2017

Indian Dermatol Online J

View full text Add to dashboard Cite

show abstract

“…After removing duplicates, we screened 813 records and reviewed the full texts of 488 studies (Figure 1). Ultimately, we included 36 studies, reported in 35 articles 42–76 . Detailed information about the study and participant characteristics, including the risk‐of‐bias evaluations and reasons for excluding studies is given in Appendix S3 and Appendix S4 (see Supporting Information).…”

Section: Resultsmentioning

confidence: 99%

“…We included one RCT 67 Another RCT 75 compared the efficacy and safety of an emulsion containing TXA 6Á5%, potassium azeloyl diglycinate and niacinamide with vehicle in 67 patients. Patients in the intervention group had a greater reduction in their MASI scores [MD -2Á80 (95% CI -5Á27 to -0Á33); GRADE: ⨁⨁⨁◯] and relative melanin value [MD -15Á10 (95% CI -22Á76 to -7Á44); GRADE: ⨁⨁⨁◯].…”

Section: Tranexamic Acidmentioning

confidence: 99%

Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trials

Pennitz

Kinberger

Valle

et al. 2022

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…[ 129 ] Individual studies have evaluated the efficacy of novel agents such as trifecting night cream, combination cream containing KA, phytic acid, and butyl methoxydibenzoylmethane, and trans-4-(aminomethyl) cyclohexanecarboxylic acid/potassium azeloyl diglycinate/niacinamide have shown superior results, but further large-scale studies are required to establish their efficacy. [ 129 130 131 132 ]…”

Section: Discussionmentioning

confidence: 99%

Topical and Systemic Therapies in Melasma: A Systematic Review

Sarkar,

Handog,

Das

et al. 2023

Indian Dermatology Online Journal

View full text Add to dashboard Cite

Introduction: Melasma is an acquired disorder, which presents with well-demarcated, brown-colored hyperpigmented macules, commonly involving the sun-exposed areas such as the face. It is a chronic and distressing condition, affecting the patients' quality of life, and has been conventionally treated with “first-line” agents including hydroquinone (HQ) alone or as a part of a triple combination cream (TCC), while “second-line” options include chemical peels, and third line options include laser therapy. Materials and Methods: A systematic search was performed for all topical and systemic treatments for melasma up till May 4, 2021, using the PubMed and EMBASE databases, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol. The search terms “melasma” and “treatment” were used to search for the relevant articles on both these databases, and a total of 4020 articles were identified. After removing the duplicate entries and screening the titles, abstracts, and full-text articles, we identified 174 randomized controlled trials (RCTs) or controlled clinical trials. Results: Based on our review, HQ, TCCs, sunscreens, kojic acid (KA), and azelaic acid receive grade A recommendation. Further large-scale studies are required to clearly establish the efficacy of topical vitamin C, resorcinol, and topical tranexamic acid (TXA). Several newer topical agents may play a role only as an add-on or second-line drugs or as maintenance therapy. Oral TXA has a strong recommendation, provided there are no contraindications. Procyanidins, Polypodium leucotomos (PL), and even synbiotics may be taken as adjuncts. Discussion: Several newer topical and systemic agents with multimodal mechanisms of action have now become available, and the balance seems to be tipping in favor of these innovative modalities. However, it is worth mentioning that the choice of agent should be individualized and subject to availability in a particular country.

show abstract

Effects of trans-4-(aminomethyl) cyclohexanecarboxylic acid/potassium azeloyl diglycinate/niacinamide topical emulsion in Thai adults with melasma: a single-center, randomized, double-blind, controlled study

Abstract: The significant differences in RMVs between the test and control groups were observed after 6 weeks of treatment, both in the primary ITT and OT populations. The incidence of patients with AEs was not significantly different between the test and control groups.

Cited by 7 publications

References 21 publications

Evidence-based review, grade of recommendation, and suggested treatment recommendations for melasma

Evidence-based review, grade of recommendation, and suggested treatment recommendations for melasma

Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trials

Topical and Systemic Therapies in Melasma: A Systematic Review

Contact Info

Product

Resources

About